Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Novo Nordisk Inc.

FDA has issued 2 warning letters to Novo Nordisk Inc.:

Letter facts

Letter date
March 5, 2026 (2026-03-05)
Issuing office
Center for Drug Evaluation and Research (CDER)
Products named
semaglutideliraglutidenedosiran sodiumestradiol
Violation categories
Other

Understanding these violation categories

Other

FDA cited violations of federal regulations governing drug research, clinical trials, or product distribution. A warning letter is an advisory notice allowing the recipient to respond.

Factual Violation Summary

FDA says nNI's written PADE procedures allowed rejection of serious unexpected ADEs based on reporter causality, invalidated cases lacking patient identifiers, and let cases stall in medical review, causing late or missed 15-day reports.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Failure to develop adequate written PADE procedures (21 CFR 314.80(b))
  • Failure to report serious and unexpected ADEs within 15 calendar days (21 CFR 314.80(c)(1)(i))
  • Improper rejection or invalidation of serious and unexpected ADE cases
  • Failure to ensure contractor and vendor compliance with PADE requirements
  • Ineffective corrective and preventive actions

More letters about Liraglutide

Recent FDA warning letters concerning Liraglutide:

Similar violations (Other)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.